These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 17400650)

  • 1. Simvastatin was cost effective across a broad range of risk and age groups.
    Bryson CL; Fihn SD
    Evid Based Med; 2007 Apr; 12(2):58. PubMed ID: 17400650
    [No Abstract]   [Full Text] [Related]  

  • 2. Simvastatin was cost-effective across a broad range of risk and age groups.
    Bryson CL; Fihn SD
    ACP J Club; 2007; 146(2):50. PubMed ID: 17335173
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
    Martens LL; Rutten FF; Kuijpens JL; Winter J
    Ned Tijdschr Geneeskd; 1991 Apr; 135(15):655-9. PubMed ID: 1903849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
    Badia X; Russo P; Attanasio E
    Clin Ther; 1999 Oct; 21(10):1788-96. PubMed ID: 10566573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
    Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
    Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
    Bottorff MB; Yenkowsky JP; Cave DG
    Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).
    Garmendia F; Brown AS; Reiber I; Adams PC
    Curr Med Res Opin; 2000; 16(3):208-19. PubMed ID: 11191012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
    Hernborg A; Hjemdahl P; Håkansson J
    Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
    Keiding H; Hildebrandt P; Alemao E; Davies GM
    Ugeskr Laeger; 2008 Jun; 170(26-32):2323-6. PubMed ID: 18570764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
    Briseño GG; Mino-León D
    Curr Med Res Opin; 2010 May; 26(5):1075-81. PubMed ID: 20225991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.